Keeping the circuit open: Lessons from the lab

Blood Purification

Volumn 20, Issue 3, 2002, Pages 275-281

  Shulman, Rob I ^a   Singer, Mervyn ^b   Rock, Jo ^b  

^a MIDDLESEX HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

Alprostadil; Aprotinin; Danaparoid; Hemofiltration; Heparin; Heparin induced thrombocytopenia; Lepirudin; Low molecular weight heparin; Tissue factor; Tissue factor plasma inhibitor

Indexed keywords

ANTITHROMBIN III; APROTININ; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; DANAPAROID; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIN 1; FRESH FROZEN PLASMA; HEPARIN; HEPARIN COFACTOR; KALLIKREIN; LOW MOLECULAR WEIGHT HEPARIN; PROSTACYCLIN; PROSTAGLANDIN E1; THROMBIN; THROMBIN ANTITHROMBIN COMPLEX; THROMBOMODULIN; THROMBOPLASTIN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR;

ANTICOAGULATION; BLOOD CLOTTING; CONFERENCE PAPER; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; ENDOTHELIUM INJURY; EXTRACORPOREAL CIRCULATION; FLOW RATE; HEMOFILTRATION; HUMAN; LABORATORY; MOLECULAR WEIGHT; PRIORITY JOURNAL; SEPSIS; THROMBOCYTOPENIA; ARTIFICIAL MEMBRANE; EQUIPMENT; INSTRUMENTATION; METHODOLOGY; REVIEW; STANDARD;

ANTICOAGULANTS; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; EQUIPMENT FAILURE; EQUIPMENT FAILURE ANALYSIS; HEMOFILTRATION; HUMANS; MEMBRANES, ARTIFICIAL;

EID: 0036356429     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000047020     Document Type: Conference Paper

References (31)

1. Acquired antithrombin III (AT-III) deficiency in septicaemia
2. Substitution of antithrombin III in shock and DIC: A randomised study
3. Human antithrombin concentrates and experimental disseminated intravascular coagulation
4. Coagulation, fribrinolysis and kallikrein systems in sepsis: Relations to outcome
5. Continuous venovenous haemofiltration using polyacrylonitrile filters does not activate contact system and intrinsic coagulation
6. Heparin clearance during continuous veno-venous haemofiltration
7. Activation of the tissue factor pathway occurs during continuous venovenous hemofiltration
8. Depletion of intravascular pools of tissue factor pathway inhibitor (TFPI) during repeated or continuous intravenous infusion of heparin in man
9. Immunodepletion of extrinisic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: Evidence supporting a physiological role for EPI as a natural anticoagulant
10. Immunodepletion of extrinisic pathway inhibitor (EPI) sensitizes rabbits to endotoxin-induced intravascular coagulation and the generalised Shwartzman reaction
11. Endothelial dysfunction in critically ill patients: The effect of haemofiltration
12. Proximally delivered dilute heparin does not improve circuit life in continuous venovenous haemodiafiltration
13. Increased anticoagulation during cardiopulmonary bypass by prostaglandin E1
14. Anticoagulation with prostacyclin and heparin during continuous venovenous haemofiltration
15. Assessment of standard ultrafiltrate production rate using prostacyclin in continuous venovenous hemofiltration
16. Anticoagulation for continuous arteriovenous hemofiltration in children
17. Improved cardiovascular stability during continuous modes of renal replacement therapy in critically ill patients with acute hepatic and renal failure
18. Anticoagulation with prostaglandin E1 and unfractionated heparin during continuous venovenous hemofiltration
19. Predilution hemofiltration: A new technology applied to an old therapy
20. Heparin-induced thrombocytopenia
21. Heparin-associated thrombocytopenia: The antibody is not heparin specific
22. Hemodialysis in heparin-induced thrombocytopenia: Epoprostenol (OPGI2) as sole agent
23. Heparin-induced thrombocytopenia during continuous haemofiltration
24. Newer strategies for the treatment of heparin-induced thrombocy-topenia
25. Monitoring anticoagulant therapy by activated thrombolastin time: Hirudin assessment
26. Continuous haemofiltration with r-hirudin (lepirudin) as anticoagulant in a patient with heparin induced thrombocytopenia (HIT II)
27. Bleeding after intermittent or continuous r-hirudin during CVVH
28. Is low-molecular-weight heparin useful for venovenous hemofiltration in the intensive care unit?
29. The key emerging role of low molecular weight heparins
30. A controlled trial of low-molecular-weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration
31. Time course of activated coagulation time at various sites during continuous haemodiafiltration using nafamostat mesilate